FDA's Advisory Committee Conflict of Interest Guidance Needs Urgent Finalization
A recent review highlights the FDA's inconsistent disclosure of financial conflicts of interest among advisory committee members, emphasizing the need for new guidance.
The FDA has been criticized for its lack of transparency regarding the financial conflicts of interest of advisory committee members. A recent review indicates that the agency has not consistently shared information on how these conflicts are determined.
This inconsistency poses risks to the integrity of advisory committees, which are essential for maintaining public trust in the regulatory process. The review calls for the FDA to finalize new guidance that would enhance transparency.
Implementing clearer guidelines could improve the oversight of advisory committees, ensuring that conflicts of interest are appropriately managed and disclosed, thus reinforcing the credibility of the FDA's advisory processes.